Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer

BACKGROUND: Aromatase inhibitors (AI) reduce recurrence and death in patients with early-stage hormone receptor-positive (HR +) breast cancer. Treatment-related toxicities, including AI-induced musculoskeletal symptoms (AIMSS), are common and may lead to early AI discontinuation. The objective of th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Genet
Autors principals: Hertz, Daniel L., Smith, Karen Lisa, Zong, Yuhua, Gersch, Christina L., Pesch, Andrea M., Lehman, Jennifer, Blackford, Amanda L., Henry, N. Lynn, Kidwell, Kelley M., Rae, James M., Stearns, Vered
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Genetics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8239354/
https://ncbi.nlm.nih.gov/pubmed/34211496
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fgene.2021.662734
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars